Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 12234993)

1.
2.

ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002.

Tørring N, Dagnaes-Hansen F, Sørensen BS, Nexø E, Hynes NE.

Prostate. 2003 Jul 1;56(2):142-9.

PMID:
12746839
5.

Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.

Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ.

Cancer Res. 2003 Jun 1;63(11):2940-7.

6.

AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.

Cancer Res. 2004 Jul 15;64(14):4931-41.

7.

Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.

Emanuel SL, Hughes TV, Adams M, Rugg CA, Fuentes-Pesquera A, Connolly PJ, Pandey N, Moreno-Mazza S, Butler J, Borowski V, Middleton SA, Gruninger RH, Story JR, Napier C, Hollister B, Greenberger LM.

Mol Pharmacol. 2008 Feb;73(2):338-48. Epub 2007 Nov 1.

8.

Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.

Suzuki T, Fujii A, Ohya J, Nakamura H, Fujita F, Koike M, Fujita M.

Cancer Sci. 2009 Aug;100(8):1526-31. doi: 10.1111/j.1349-7006.2009.01197.x. Epub 2009 May 13.

PMID:
19459856
9.
10.
11.

Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo.

Nagasawa J, Mizokami A, Koshida K, Yoshida S, Naito K, Namiki M.

Int J Urol. 2006 May;13(5):587-92.

PMID:
16771730
12.

Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.

Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D.

Clin Cancer Res. 2004 Dec 15;10(24):8728-34.

13.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
15.

Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.

Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D.

Cancer Res. 2002 Oct 1;62(19):5485-8.

16.

Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.

Terracciano D, Mazzarella C, Di Carlo A, Mariano A, Ferro M, Di Lorenzo G, Giordano A, Altieri V, De Placido S, Macchia V.

Oncol Rep. 2010 Jul;24(1):213-7.

PMID:
20514464
18.
20.

Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.

Zhou Y, Li S, Hu YP, Wang J, Hauser J, Conway AN, Vinci MA, Humphrey L, Zborowska E, Willson JK, Brattain MG.

Cancer Res. 2006 Jan 1;66(1):404-11.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk